Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous ...

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system ...

This study explores the therapeutic potential of Mazindol ER, a triple monoamine reuptake inhibitor with additional activity on 5-HT1A, MOP, and OX2R receptors, for fentanyl dependence.

The drug is a long-acting and potent serotonin 5-HT1A receptor agonist and will be added to DSP’s psychiatry and neurology research pipeline. Paul Workman, chief executive of The Institute of ...

The 5-HT2A receptor plays an important role in emotional responses ... pharmaceutical composition, and treatment. The human 5-HT1A radioligand binding assay was performed. The compounds described in ...

According to the partners, DSP-0038 combines serotonin 5-HT2A receptor antagonism and 5-HT1A receptor agonism – two well established targets for antipsychotic drugs – in a single small molecule.

leading to downregulation of these receptors and changes in neuronal excitability in the cortex. While the 5-HT1A receptor may also play a role in their antidepressant effect, more research is ...